Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Joseph J. Larosa net worth and biography

Joseph Larosa Biography and Net Worth

EVP of Regeneron Pharmaceuticals

Joseph J. LaRosa joined Regeneron in 2011 and is currently Executive Vice President, General Counsel and Secretary. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. He also previously served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD degree from New York University.

What is Joseph J. Larosa's net worth?: The estimated net worth of Joseph J. Larosa is at least $33.67 million as of February 22nd, 2024. Mr. Larosa owns 37,543 shares of Regeneron Pharmaceuticals stock worth more than $33,669,313 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Larosa may own. Learn More about Joseph J. Larosa's net worth.
How do I contact Joseph J. Larosa?: The corporate mailing address for Mr. Larosa and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Joseph J. Larosa's contact information.
Has Joseph J. Larosa been buying or selling shares of Regeneron Pharmaceuticals?: Joseph J. Larosa has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Most recently, Joseph J. Larosa sold 1,000 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $967.65, for a transaction totalling $967,650.00. Following the completion of the sale, the executive vice president now directly owns 37,543 shares of the company's stock, valued at $36,328,483.95. Learn More on Joseph J. Larosa's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 59,085 shares worth more than $51,077,528.46. The most recent insider tranaction occured on March, 14th when EVP Andrew J Murphy sold 5,783 shares worth more than $5,531,266.01. Insiders at Regeneron Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 3/14/2024.

Joseph J. Larosa Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2024	Sell	1,000	$967.65	$967,650.00	37,543
2/7/2024	Sell	1,000	$950.00	$950,000.00	38,543
4/7/2022	Sell	5,114	$721.10	$3,687,705.40	16,900
8/23/2021	Sell	3,425	$661.84	$2,266,802.00	23,182
7/6/2021	Sell	3,398	$580.00	$1,970,840.00	23,182
8/31/2020	Sell	4,672	$615.04	$2,873,466.88	20,438
4/20/2020	Sell	1,778	$570.30	$1,013,993.40	15,547
4/17/2020	Sell	2,267	$557.38	$1,263,580.46	19,438
4/2/2020	Sell	6,797	$489.98	$3,330,394.06	19,438
3/16/2015	Sell	18,311	$450.00	$8,239,950.00

Joseph J. Larosa Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $896.82

$891.46

$920.73

50 Day Range

MA: $954.14

$893.99

$993.35

2 Week Range

Now: $896.82

$684.80

$998.33

Volume

507,464 shs

Average Volume

495,118 shs

Market Capitalization

$98.43 billion

P/E Ratio

25.81

Dividend Yield

N/A

Beta

0.11

Tiny Biotech Stock Wins $75 Billion Patent

From Behind the Markets | Ad

Find out more here >>>